7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2,6-dioxo-
- CAS No.
- 1372206-64-8
- Chemical Name:
- 7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2,6-dioxo-
- Synonyms
- 2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-isopropyl-N-(isopropylcarbamoyl)acetamide;1,2,3,6-tetrahydro-1,3-dimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2,6-dioxo-7H-Purine-7-acetamide;7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2,6-dioxo-
- CBNumber:
- CB64657954
- Molecular Formula:
- C16H24N6O4
- Molecular Weight:
- 364.4
- MDL Number:
- MOL File:
- 1372206-64-8.mol
7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2,6-dioxo- Properties
| Density | 1.35±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | 4°C, protect from light |
| solubility | DMSO : 100 mg/mL (274.42 mM; Need ultrasonic) |
| pka | 12.56±0.46(Predicted) |
| form | Solid |
| color | White to off-white |
7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2,6-dioxo- Chemical Properties,Uses,Production
Uses
THX-B is a potent and non-peptidic p75NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders[1][2][3].
in vivo
THX-B (50 μg in 125 μL PBS, i.p. weekly for 4 weeks) improves bladder function in a mouse model of diabetic voiding dysfunction[3].
THX-B (2?μL of 2?μg/μL, IVT injection, a single dose) elicits a neuroprotective effect on photoreceptor cells in P17 rd10 mice[2].
THX-B (40 μg in 20 μL, IVT injection) resolves the inflammatory, vascular, and neurodegenerative phases of the retinal pathology[4].
| Animal Model: | Mouse model of diabetic voiding dysfunction |
| Dosage: | 50 μg in 125 μL PBS |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Prevented bladder weight increase, which was 18% (95% CI 3%, 32%) and 37% (95% CI 14%, 60%) lower after 2 and 4 weeks of treatment. |
| Animal Model: | P17 rd10 mice[1] |
| Dosage: | 2?μL of 2?μg/μL, single dose |
| Administration: | Intravitreal (IVT) injected in one eye |
| Result: | Increased the number of photoreceptor rows as well as the ONL/INL ratio. Decreased the total number of microglial cells in the treated retinas, as well as some of the inflammatory signs, such as GFAP, α2M and the proinflammatory cytokines IL-1β and TNFα. |
References
[1] Keren Ettinger, et al. Nerve growth factor stimulation of ERK1/2 phosphorylation requires both p75NTR and α9β1 integrin and confers myoprotection towards ischemia in C2C12 skeletal muscle cell model. Cell Signal. 2012 Dec;24(12):2378-88. DOI:10.1016/j.cellsig.2012.08.008
[2] María Platón-Corchado, et al. p75NTR antagonists attenuate photoreceptor cell loss in murine models of retinitis pigmentosa. Cell Death Dis. 2017 Jul 13;8(7):e2922. DOI:10.1038/cddis.2017.306
[3] Abubakr H Mossa, et al. Antagonism of proNGF or its receptor p75 NTR reverses remodelling and improves bladder function in a mouse model of diabetic voiding dysfunction. Diabetologia. 2020 Sep;63(9):1932-1946. DOI:10.1007/s00125-020-05222-4
[4] Alba Galan, et al. Subconjunctival Delivery of p75NTR Antagonists Reduces the Inflammatory, Vascular, and Neurodegenerative Pathologies of Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2852-2862. DOI:10.1167/iovs.16-20988
7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2,6-dioxo- Preparation Products And Raw materials
Raw materials
Preparation Products
7H-Purine-7-acetamide, 1,2,3,6-tetrahydro-1,3-dimethyl-N-(1-methylethyl)-N-[[(1-methylethyl)amino]carbonyl]-2,6-dioxo- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; | support@targetmol.com | United States | 39035 | 58 |
| Hangzhou IKSChem Technology Co., Limited | +8613625816949 | zheng@ikschem.com | China | 919 | 58 |
| Suzhou Rovathin Foreign Trade Co.,Ltd | 0512-65816829 18662214788 | info@rovathin.com.cn | China | 9987 | 58 |
| Shanghai Hecheng Medical Technology Co., LTD | 13564747822 | 669027880@qq.com | China | 959 | 58 |
| Bide Pharmatech Ltd. | 400-1647117 13681763483 | product02@bidepharm.com | China | 59936 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11973 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29257 | 58 |





